PTK2 and ovarian serous adenocarcinoma: Additionally, we will highlight ongoing FAK inhibitor phase II and III clinical trials in high- and low-grade serous ovarian cancers, respectively, that are incorporating combinatorial approaches to address unmet clinical needs.